|
|
Vaccine Comparison
|
CCPS-P64kR |
| Vaccine Information |
- Vaccine Name: CCPS-P64kR
- Vaccine Ontology ID: VO_0004165
- Type: Conjugate vaccine
- Status: Research
- lpdA
gene engineering:
- Type: Recombinant protein preparation
- Detailed Gene Information: Click Here.
- Adjuvant: aluminum hydroxide vaccine adjuvant
- Immunization Route: Not specified
|
| References |
|
|
|
COMVAX |
| Vaccine Information |
- Vaccine Name: COMVAX
- Product Name: Haemophilus b Conjugate
- Tradename: COMVAX
- Manufacturer: Merck & Co., Inc
- Vaccine Ontology ID: VO_0000028
- CDC CVX code: 51
- Type: Conjugate vaccine
- Status: Licensed
- Location Licensed: USA (License #0002)
- Host Species for Licensed Use: Human
- Adjuvant: aluminum hydroxide vaccine adjuvant
- VO ID: VO_0000127
- Description: Description: It is a vaccination against invasive disease caused by Haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis B virus in infants 6 weeks to 15 months of age born of HBsAg negative mothers.
- Preparation: It is grown in complex fermentation media. It is then purified from the culture broth by purification procedures which include ethanol fractionation, enzyme digestion, phenol extraction and diafiltration (FDA: COMVAX).
- Immunization Route: Intramuscular injection (i.m.)
- Storage: Store vaccine at 2-8°C (36-46*F). Storage above or belew the recommended temperature may reduce potency. DO NOT FREEZE since freezing destroys potency.(Comvax)
- Approved Age for Licensed Use: 2-15 months of age.
- Contraindication: Hypersensitivity to any component of the vaccine.
- Description: Immunization of persons 6 weeks to 15 months of age born to hepatitis B surface antigen (HBsAg) negative mothers.
|
| References |
Comvax: Comvax [http://www.fda.gov/cber/products/comvax.htm]
FDA: COMVAX: FDA: COMVAX information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm174757.htm]
|
|
MBP fused on Campylobacter FlaA (MBP-FlaA) |
| Vaccine Information |
- Vaccine Name: MBP fused on Campylobacter FlaA (MBP-FlaA)
- Vaccine Ontology ID: VO_0004101
- Type: Conjugate vaccine
- Antigen: recombinant protein comprising the maltose-binding protein (MBP) of E. coli fused to amino acids 5 to 337 of the FlaA flagellin of Campylobacter coli VC167 (Lee et al., 1999)
- FlaA from C. jejuni NCTC 11168
gene engineering:
- Type: flagellin protein
- Detailed Gene Information: Click Here.
- Adjuvant: LTR192G vaccine adjuvant
- VO ID: VO_0001321
- Description: immunization occurs with the mutant E. coli heat-labile enterotoxin (LT( R192G)) as a mucosal adjuvant (Lee et al., 1999)
- Preparation: Part of the flaA gene ( 780 base pairs ) was cloned in plasmid pBEB downstream and in frame with the LT-B to allow expression of a hybrid protein . Transformed E coli chi 6097 expressed the hybrid protein ( 43 kdaltons ) in inclusion bodies at mid log phase . The inclusion bodies were isolated , and the identity of the protein was verified by western blot . (Khoury et al., 1995)
- Virulence: The full range of MBP-FlaA doses were effective in eliciting antigen-specific serum IgG responses, and these responses were enhanced by adjuvant use. Stimulation of FlaA-specific intestinal secretory IgA (sIgA) responses required immunization with higher doses of MBP-FlaA or coadministration of lower doses with the adjuvant (Lee et al., 1999).
- Description: A mucosal vaccine was used in an effort to elicit serum IgG and intestinal secretory IgA. A genetic hybrid of the Campylobacter jejuni flaA gene with LT-B of Escherichia coli and assessment of the efficacy of the hybrid protein has been developed an oral chicken vaccine (Wilkinson et al., 2003).
|
| References |
Khoury et al., 1995: Khoury CA, Meinersmann RJ. A genetic hybrid of the Campylobacter jejuni flaA gene with LT-B of Escherichia coli and assessment of the efficacy of the hybrid protein as an oral chicken vaccine. Avian diseases. 1995 Oct-Dec; 39(4); 812-20. [PubMed: 8719215 ].
Lee et al., 1999: Lee LH, Burg E 3rd, Baqar S, Bourgeois AL, Burr DH, Ewing CP, Trust TJ, Guerry P. Evaluation of a truncated recombinant flagellin subunit vaccine against Campylobacter jejuni. Infection and immunity. 1999 Nov; 67(11); 5799-805. [PubMed: 10531231].
Wilkinson et al., 2003: Wilkinson J, Rood D, Minior D, Guillard K, Darre M, Silbart LK. Immune response to a mucosally administered aflatoxin B1 vaccine. Poultry science. 2003 Oct; 82(10); 1565-72. [PubMed: 14601734].
|
|
Menjugate |
| Vaccine Information |
- Vaccine Name: Menjugate
- Product Name: Meningococcal Group C CRM-197 Conjugate Vaccine
- Tradename: Menjugate
- Manufacturer: Novartis Vaccines and Diagnostics
- Vaccine Ontology ID: VO_0010726
- Type: Conjugate vaccine
- Status: Licensed
- Location Licensed: Canada
- Host Species for Licensed Use: Human
- Adjuvant: aluminum hydroxide vaccine adjuvant
- Immunization Route: Intramuscular injection (i.m.)
- Storage: Do not store above 25° C.
- Approved Age for Licensed Use: 2 months and older.
- Description: Products: Conjugate.
|
| References |
|
|
|
Neisvac-C |
| Vaccine Information |
- Vaccine Name: Neisvac-C
- Product Name: Meningococcal Group C-TT Conjugate Vaccine, Adsorbed
- Tradename: Neisvac-C
- Manufacturer: Baxter Healthcare Corporation, GlaxoSmithKline
- Vaccine Ontology ID: VO_0010729
- Type: Conjugate vaccine
- Status: Licensed
- Location Licensed: Canada
- Host Species for Licensed Use: Human
- Adjuvant: aluminum hydroxide vaccine adjuvant
- Immunization Route: Intramuscular injection (i.m.)
- Storage: Store at 2°C to 8°C.
- Approved Age for Licensed Use: 2 months of age and older.
- Description: Products: Conjugate.
|
| References |
|
|
|
Non-typeable H. influenzae dLOS–P6 vaccine |
| Vaccine Information |
- Vaccine Name: Non-typeable H. influenzae dLOS–P6 vaccine
- Vaccine Ontology ID: VO_0004115
- Type: Conjugate vaccine
- Antigen: NTHi detoxified lipooligosaccharide (dLOS) conjugated with outer membrane protein P6
- Adjuvant: Ribi vaccine adjuvant
- Preparation: LOS was purified from a clinical isolate of NTHi strain 9274 and five major LOS prototype strainsby a modified phenol–water extraction method. A hydrazinolysis was used to produce the detoxified LOS (dLOS). An adipic acid dihydrazide (ADH, Aldrich Chemical Co., Milwaukee, WI) was then bound covalently to the dLOS to form an adipic hydrazide derivative, AH-dLOS. P6 was isolated from strain 9274 (Wu et al., 2005). P6 was covalently conjugated to dLOS of strain 9274 through adipic acid dihydrazide with different ratios of dLOS to P6. It resulted in two conjugate formulations with weight ratios of dLOS to P6 of 3.7 for dLOS–P6 (I) and 1.6 for dLOS–P6 (II). Binding activity of the conjugates was examined by ELISA with mouse monoclonal antibodies specific to LOS and P6 and a rabbit anti-P6 serum. The results showed that the conjugates bound not only to the LOS antibody but also to both P6 antibodies. It suggested that the conjugates retained epitopes of both LOS and P6 antigens (Wu et al., 2005).
- Virulence: detoxified
|
| References |
Wu et al., 2005: Wu T, Chen J, Murphy TF, Green BA, Gu XX. Investigation of non-typeable Haemophilus influenzae outer membrane protein P6 as a new carrier for lipooligosaccharide conjugate vaccines. Vaccine. 2005 Oct 25; 23(44); 5177-85. [PubMed: 16039021].
|
|
PedvaxHIB |
| Vaccine Information |
- Vaccine Name: PedvaxHIB
- Product Name: Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)
- Tradename: PedvaxHIB
- Manufacturer: Merck & Co, Inc.
- Vaccine Ontology ID: VO_0000083
- CDC CVX code: 49
- Type: Conjugate vaccine
- Status: Licensed
- Location Licensed: USA
- Host Species for Licensed Use: Human
- Antigen: Haemophilus b capsular polyribosyl-ribitol-phosphate( PRP)-Neisseria meningitidis outer membrane protein complex (OMPC)
- Adjuvant: aluminum hydroxide vaccine adjuvant
- VO ID: VO_0000127
- Description: PedvaxHIB is a highly purified capsular polysaccharide (polyribosylribitol phosphate or PRP) of Haemophilus influenzae type b (Haemophilus b, Ross strain) that is covalently bound to an outer membrane protein complex (OMPC) of the B11 strain of Neisseria meningitidis serogroup B. The covalent bonding of the PRP to the OMPC which is necessary for enhanced immunogenicity of the PRP is confirmed by quantitative analysis of the conjugate’s components following chemical treatment which yields a unique amino acid
- Preparation: Haemophilus influenzae type b and Neisseria meningitidis serogroup B are grown in complex fermentation media. The PRP is purified from the culture broth by purification procedures which include ethanol ractionation, enzyme digestion, phenol extraction and diafiltration. The OMPC from Neisseria meningitidis is purified by detergent extraction, ultracentrifugation, diafiltration and sterile filtration (PedvasHIB).
- Immunization Route: Intramuscular injection (i.m.)
- Virulence: No virulence
- Storage: Store vaccine at 2-8°C (36-46°F).
- Approved Age for Licensed Use: Infants and children 2 to 71 months of age (PedvasHIB).
- Contraindication: Hypersensitivity to any component of the vaccine or the diluent or persons who develop symptoms suggestive of hypersensitivity after an injection should not receive further injections of the vaccine.
- Description: PedvaxHIB is a highly purified capsular polysaccharide (polyribosylribitol phosphate or PRP) of Haemophilus influenzae type b (Haemophilus b, Ross strain) that is covalently bound to an outer membrane protein complex (OMPC) of the B11 strain of Neisseria meningitidis serogroup B. The covalent bonding of the PRP to the OMPC which is necessary for enhanced immunogenicity of the PRP is confirmed by quantitative analysis of the conjugate’s components following chemical treatment which yields a unique amino acid (PedvasHIB).
Nonconjugated PRP vaccines are capable of stimulating B-lymphocytes to produce antibody without the help of T-lymphocytes (T-independent). The responses to many other antigens are augmented by helper T-lymphocytes (T-dependent). PedvaxHIB is a PRP-conjugate vaccine in which the PRP is covalently bound to the OMPC carrier29 producing an antigen which is postulated to convert the T-independent antigen (PRP alone) into a T-dependent antigen resulting in both an enhanced antibody response and immunologic memory (Marburg 1986).
|
| References |
Marburg 1986: S. Marburg, D. Jorn, R. L. Tolman, B. Arison, J. McCauley, P. J. Kniskern, A. Hagopian, and P. P. Vella. Bimolecular chemistry of macromolecules: synthesis of bacterial polysaccharide conjugates with Neisseria meningitidis membrane protein. Journal of the American Chemical Society. 1986; 108; 5282-5287.
PedvasHIB: Liquid PedvaxHIB [http://www.merck.com/product/usa/pi_circulars/p/pedvax_hib]
|
|
